Description
The 1F11/TSLPR monoclonal antibody specifically binds to Thymic Stromal Lymphopoietin Receptor (TSLPR). TSLPR is a member of the hematopoietin receptor superfamily and is also known as Cytokine Receptor-like Factor 2 (CRL2, CRLF2Y, CRLF2). The functional TSLPR complex consists of two subunits, TSLPR and the alpha subunit of the Interleukin-7 Receptor (IL-7Rα). Analysis of the TSLPR reveals sequence similarity with the common cytokine receptor gamma chain (γc; CD132). Functional TSLPRs are expressed by epithelial cells and a variety of hematopoietic cell types, including thymocytes, T cells, B cells, natural killer T cells, monocytes, macrophages, basophils, and dendritic cells (DC). Recent studies indicate that TSLP can activate multiple STAT (Signal Transducer and Activator of Transcription) signaling proteins. TSLP enhances the maturation and viability of DC. It strongly induces DC expression of the CD40 and CD80 costimulatory molecules and chemokines, e.g., TARC (Thymus and activation-regulated chemokine; CCL17) that can attract Th2 effector cells. TSLP supports B cell development. TSLP costimulates the proliferation of naïve T cells in the presence of mature DC. TSLP is also able to increase the sensitivity of T cell receptor-activated CD4+ T cells to low doses of IL-2. In the presence of TSLP, the acute myeloid leukemia-derived cell line, MUTZ-3, shows induced growth and reduced apoptosis. CRLF2 deregulated gene expression is thought to be involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. The 1F11/TSLPR antibody is reportedly a neutralizing antibody.
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
3. For U.S. patents that may apply, see bd.com/patents.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
6. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
7. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
8. When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
9. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
10. An isotype control should be used at the same concentration as the antibody of interest.
11. Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
